The Pediatric Endocrinology Clinic at the
University of Florida (Gainesville, FL USA) will begin using the Advisor Pro
Decision-Support System developed by DreaMed Diabetes (Tel Aviv, Israel) for
type 1 and 2 diabetic patients. The system will be integrated into existing
diabetic management protocols to provide remote insulin management with data
analysis and disease management tools.
The University of Florida clinic’s decision eliminates the need for multiple platforms in diabetic care. In addition to providing patient support, the agreement allows the clinic to deploy features to streamline and optimise payer reimbursements and provide administrative and financial support.
This move follows last month FDA clearance to expand use to treat type 2 diabetes patients. Previously, DreMed had FDA approval only to treat Type 1 diabetes. This makes Advisor Pro the first decision support system to receive FDA clearances for Type 1 and Type 2 diabetes in adults and children.
Over 10% of people in the U.S. have diabetes. Of this, about 210,000 patients under age 20 are diagnosed with diabetes, according to the American Diabetes Association. The decision-support system algorithmically optimises insulin delivery and assist healthcare providers in caring for diabetic patients who use insulin pumps or injections and monitor their glucose.
The system was previously tested in a multicenter, multinational, six-month study, where the Pediatric Endocrinology Clinic at the University of Florida participated. The study compared clinical outcomes using Advisor Pro to those gained with physician-guided recommendations and found the performance to be equal.
Dr Michael J. Haller, Chief of Pediatric Endocrinology Clinic at the University of Florida, adds: ‘Digital medicine applications can vastly improve the access of patients to healthcare. Remote medicine is part of the future of healthcare, and clinics need to deploy remote care solutions to deliver better care to their patients.’
Source: Business Wire